19:39 , May 26, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends against Helsinn's Adlumiz

EMA’s CHMP recommended against approval of an MAA from Helsinn Healthcare S.A. (Lugano, Switzerland) for Adlumiz anamorelin (ONO-7643) to treat anorexia, cachexia or unintended weight loss in non-small cell lung cancer (NSCLC) patients. CHMP said their...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Anamorelin regulatory update

EMA accepted for review an MAA from Helsinn for anamorelin to treat anorexia, cachexia or unintended weight loss in non-small cell lung cancer (NSCLC) patients. Helsinn gained the small molecule ghrelin agonist through its...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Helsinn, Mundipharma deal

The companies added China, including Hong Kong and Macau, to a February deal granting Mundipharma commercialization rights to Helsinn’s anamorelin. The small molecule ghrelin agonist has completed Phase III trials in non-small cell...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Company News

Helsinn, Mundipharma deal

Helsinn granted Mundipharma exclusive rights to commercialize anamorelin in Brazil and “key markets” in the Middle East and North Africa. The once-daily small molecule ghrelin agonist has completed the Phase III trial ROMANA...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Anamorelin: Phase III data

The double-blind, international Phase III ROMANA 1 trial in 477 non-small cell lung cancer (NSCLC) patients with cachexia showed that once-daily 100 mg anamorelin met the co-primary endpoint of increasing median lean body mass from...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Anamorelin: Phase III data

The double-blind, international Phase III ROMANA 2 trial in 477 non-small cell lung cancer (NSCLC) patients with cachexia showed that once-daily 100 mg anamorelin met the co-primary endpoint of increasing median lean body mass from...
07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Helsinn, Gen Pharmaceuticals deal

Helsinn granted Gen Pharmaceuticals exclusive rights to anamorelin ( ONO-7643) in Turkey. Helsinn will be responsible for development activities and supply of anamorelin for commercial use. Gen Pharmaceuticals will be responsible for regulatory approval...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Angelini, Helsinn sales and marketing update

Helsinn granted Angelini's CSC Pharmaceuticals Handels GmbH subsidiary exclusive rights to commercialize anamorelin ( ONO-7643) in Austria, Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovak Republic and the Commonwealth of Independent States (CIS). The product...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Helsinn, Chugai sales and marketing update

Helsinn granted Chugai's Chugai Pharma Marketing Ltd. subsidiary commercialization rights to anamorelin ( ONO-7643) in Germany, France, Benelux, the U.K. and Ireland. The product is in Phase III testing to treat anorexia-cachexia syndrome related...